Tomonari Harada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomonari Harada has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Masaru Obokata
Department of Cardiovascular medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
10 shared publications - Kazuki Kagami
Department of Cardiovascular medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
8 shared publications - Hideki Ishii
Department of Cardiovascular medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
6 shared publications - Naoki Yuasa
Department of Cardiovascular medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
5 shared publications - Naoki Wada
Department of Rehabilitation Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
4 shared publications - Toshimitsu Kato
Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine , 3-39-22 Showa-machi, Maebashi, Gunma 371-8511
4 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Prevalence, Exercise Performance, and Prognosis of Heart Failure With Preserved Ejection Fraction in Asian Patients With Obesity
Tani Y, et al. Korean Circ J. 2027 ;57:e57. https://doi.org/10.4070/kcj.2026.0041
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Open AccessPrevalence, Exercise Performance, and Prognosis of Heart Failure With Preserved Ejection Fraction in Asian Patients With Obesity
Tani Y, et al. Korean Circ J. 2027 ;57:e57. https://doi.org/10.4070/kcj.2026.0041
- Open Access
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Prognostic Performance of the BREATH 2 Score in Patients With Suspected Heart Failure With Preserved Ejection Fraction
Kuno T, et al. Korean Circ J. 2027 ;57:e46. https://doi.org/10.4070/kcj.2026.0168
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Open AccessPrognostic Performance of the BREATH 2 Score in Patients With Suspected Heart Failure With Preserved Ejection Fraction
Kuno T, et al. Korean Circ J. 2027 ;57:e46. https://doi.org/10.4070/kcj.2026.0168
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (1) , 100-102
Sodium-glucose Co-transporter 2 Inhibitors on Body Composition in Lean Heart Failure With Preserved Ejection Fraction
Shimoya Y, et al. Korean Circ J. 2026 Jan;56:e44. https://doi.org/10.4070/kcj.2025.0348
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (1) , 100-102
Open AccessSodium-glucose Co-transporter 2 Inhibitors on Body Composition in Lean Heart Failure With Preserved Ejection Fraction
Shimoya Y, et al. Korean Circ J. 2026 Jan;56:e44. https://doi.org/10.4070/kcj.2025.0348
- 12 August 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (14) , 2567-2568
Visceral adiposity, aortic stiffness, and cardiovascular risk
- 12 August 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (14) , 2567-2568
Visceral adiposity, aortic stiffness, and cardiovascular risk
- Open Access
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (10) , 892-903
Prevalence, Pathophysiology, and Prognostic Importance of Malnutrition Risk in Early-Stage Patients With Heart Failure and Preserved Ejection Fraction
Tani Y, et al. Korean Circ J. 2025 May;55:e82. https://doi.org/10.4070/kcj.2024.0366
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (10) , 892-903
Open AccessPrevalence, Pathophysiology, and Prognostic Importance of Malnutrition Risk in Early-Stage Patients With Heart Failure and Preserved Ejection Fraction
Tani Y, et al. Korean Circ J. 2025 May;55:e82. https://doi.org/10.4070/kcj.2024.0366
- 24 September 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (13) , 997-1009
Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial
BACKGROUND: Systemic arterial compliance and venous capacitance are typically impaired in patients with heart failure with preserved ejection fraction (HFpEF), contributing to hemodynamic congestion with stress. Sodium-glucose cotransporter-2 inhibitors reduce hemodynamic congestion and improve clinical outcomes in patients with HFpEF, but the mechanisms remain unclear. This study tested the hypothesis that Dapagliflozin would improve systemic arterial compliance and venous capacitance during exercise in patients with HFpEF. METHODS: In this secondary analysis from the CAMEO-DAPA trial (Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial), 37 patients with HFpEF (mean age 68 ± 9 years, women 65%) underwent invasive hemodynamic exercise testing with simultaneous echocardiography at baseline and following treatment for 24 weeks with Dapagliflozin or placebo. Radial artery pressure (BP) was measured continuously using a fluid-filled catheter with transformation to aortic pressure, central hemodynamics were measured using high-fidelity micromanometers, and stressed blood volume was estimated from hemodynamic indices fit to a comprehensive cardiovascular model. RESULTS: There was no statistically significant effect of Dapagliflozin on resting BP, but Dapagliflozin reduced systolic BP during peak exercise (estimated treatment difference [ETD], −18.8 mm Hg [95% CI, −33.9 to −3.7] P =0.016). Reduction in BP was related to improved exertional total arterial compliance (ETD, 0.06 mL/mm Hg/m 2 [95% CI, 0.003–0.11] P =0.039) and aortic root characteristic impedance (ETD, −2.6 mm Hg/mL*sec [95% CI: −5.1 to −0.03] P =0.048), with no significant effect on systemic vascular resistance. Dapagliflozin reduced estimated stressed blood volume at rest and during peak exercise (ETD, −292 mm Hg [95% CI, −530 to −53] P =0.018), and improved venous capacitance evidenced by a decline in ratio of estimated stressed blood volume to total blood volume (ETD, −7.3% [95% CI, −13.3 to −1.3] P =0.020). Each of these effects of Dapagliflozin at peak exercise were also observed during matched 20W exercise intensity. Improvements in total arterial compliance and estimated stressed blood volume were correlated with decreases in body weight, and reduction in systolic BP with treatment was correlated with the change in estimated stressed blood volume during exercise (r=0.40, P =0.019). Decreases in BP were correlated with reduction in pulmonary capillary wedge pressure during exercise (r=0.56, P <0.001). CONCLUSIONS: In patients with HFpEF, treatment with Dapagliflozin improved systemic arterial compliance and venous capacitance during exercise, while reducing aortic characteristic impedance, suggesting a reduction in arterial wall stiffness. These vascular effects may partially explain the clinical benefits with sodium-glucose cotransporter-2 inhibitors in HFpEF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04730947.
- 24 September 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (13) , 997-1009
Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial
BACKGROUND: Systemic arterial compliance and venous capacitance are typically impaired in patients with heart failure with preserved ejection fraction (HFpEF), contributing to hemodynamic congestion with stress. Sodium-glucose cotransporter-2 inhibitors reduce hemodynamic congestion and improve clinical outcomes in patients with HFpEF, but the mechanisms remain unclear. This study tested the hypothesis that Dapagliflozin would improve systemic arterial compliance and venous capacitance during exercise in patients with HFpEF. METHODS: In this secondary analysis from the CAMEO-DAPA trial (Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial), 37 patients with HFpEF (mean age 68 ± 9 years, women 65%) underwent invasive hemodynamic exercise testing with simultaneous echocardiography at baseline and following treatment for 24 weeks with Dapagliflozin or placebo. Radial artery pressure (BP) was measured continuously using a fluid-filled catheter with transformation to aortic pressure, central hemodynamics were measured using high-fidelity micromanometers, and stressed blood volume was estimated from hemodynamic indices fit to a comprehensive cardiovascular model. RESULTS: There was no statistically significant effect of Dapagliflozin on resting BP, but Dapagliflozin reduced systolic BP during peak exercise (estimated treatment difference [ETD], −18.8 mm Hg [95% CI, −33.9 to −3.7] P =0.016). Reduction in BP was related to improved exertional total arterial compliance (ETD, 0.06 mL/mm Hg/m 2 [95% CI, 0.003–0.11] P =0.039) and aortic root characteristic impedance (ETD, −2.6 mm Hg/mL*sec [95% CI: −5.1 to −0.03] P =0.048), with no significant effect on systemic vascular resistance. Dapagliflozin reduced estimated stressed blood volume at rest and during peak exercise (ETD, −292 mm Hg [95% CI, −530 to −53] P =0.018), and improved venous capacitance evidenced by a decline in ratio of estimated stressed blood volume to total blood volume (ETD, −7.3% [95% CI, −13.3 to −1.3] P =0.020). Each of these effects of Dapagliflozin at peak exercise were also observed during matched 20W exercise intensity. Improvements in total arterial compliance and estimated stressed blood volume were correlated with decreases in body weight, and reduction in systolic BP with treatment was correlated with the change in estimated stressed blood volume during exercise (r=0.40, P =0.019). Decreases in BP were correlated with reduction in pulmonary capillary wedge pressure during exercise (r=0.56, P <0.001). CONCLUSIONS: In patients with HFpEF, treatment with Dapagliflozin improved systemic arterial compliance and venous capacitance during exercise, while reducing aortic characteristic impedance, suggesting a reduction in arterial wall stiffness. These vascular effects may partially explain the clinical benefits with sodium-glucose cotransporter-2 inhibitors in HFpEF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04730947.
- 1 August 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (8) , e016549
Impaired Left Atrial Reserve Function in Heart Failure With Preserved Ejection Fraction
BACKGROUND: Left atrial (LA) dysfunction is common in heart failure (HF) with preserved ejection fraction. However, data on the pathophysiologic impacts of impaired LA functional reserve remained limited. We sought to determine the association of abnormal LA dynamics during exercise with cardiovascular reserve, exercise capacity, and clinical outcomes. METHODS: Patients with HF with preserved ejection fraction (n=231) and controls without HF (n=219) underwent exercise stress echocardiography with simultaneous expired gas analysis. LA function was assessed at rest and during exercise using speckle-tracking echocardiography. RESULTS: Patients with HF with preserved ejection fraction demonstrated less increase in LA reservoir and booster pump strain during exercise than those in controls. The degree of LA dilation was more closely related to exercise LA reservoir strain than to resting LA strain (Meng test, P =0.002). The presence of impaired LA reservoir strain during exercise was associated with poorer biventricular systolic reserve and cardiac output augmentation, more severe right ventricular-pulmonary artery uncoupling, and lower peak oxygen consumption. Patients with a lower exercise LA reservoir strain had a 2.7-fold increased risk of HF events (hazard ratio, 2.66 [95% CI, 1.32–5.38]; P =0.006). Among patients with follow-up echocardiography, initiation of guideline-directed medical therapy or atrial fibrillation ablation showed significant improvements in LA reservoir ( P P =0.022) and booster pump strain ( P =0.011 and 0.028) at rest and during exercise, respectively. CONCLUSIONS: Impaired LA reservoir function during exercise in HF with preserved ejection fraction is associated with biventricular reserve limitations, exercise intolerance, and increased risks of HF events.
- 1 August 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (8) , e016549
Impaired Left Atrial Reserve Function in Heart Failure With Preserved Ejection Fraction
BACKGROUND: Left atrial (LA) dysfunction is common in heart failure (HF) with preserved ejection fraction. However, data on the pathophysiologic impacts of impaired LA functional reserve remained limited. We sought to determine the association of abnormal LA dynamics during exercise with cardiovascular reserve, exercise capacity, and clinical outcomes. METHODS: Patients with HF with preserved ejection fraction (n=231) and controls without HF (n=219) underwent exercise stress echocardiography with simultaneous expired gas analysis. LA function was assessed at rest and during exercise using speckle-tracking echocardiography. RESULTS: Patients with HF with preserved ejection fraction demonstrated less increase in LA reservoir and booster pump strain during exercise than those in controls. The degree of LA dilation was more closely related to exercise LA reservoir strain than to resting LA strain (Meng test, P =0.002). The presence of impaired LA reservoir strain during exercise was associated with poorer biventricular systolic reserve and cardiac output augmentation, more severe right ventricular-pulmonary artery uncoupling, and lower peak oxygen consumption. Patients with a lower exercise LA reservoir strain had a 2.7-fold increased risk of HF events (hazard ratio, 2.66 [95% CI, 1.32–5.38]; P =0.006). Among patients with follow-up echocardiography, initiation of guideline-directed medical therapy or atrial fibrillation ablation showed significant improvements in LA reservoir ( P P =0.022) and booster pump strain ( P =0.011 and 0.028) at rest and during exercise, respectively. CONCLUSIONS: Impaired LA reservoir function during exercise in HF with preserved ejection fraction is associated with biventricular reserve limitations, exercise intolerance, and increased risks of HF events.
- 18 June 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (25) , 2026-2028
Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction
- 18 June 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (25) , 2026-2028
Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction
- 1 January 2024
- Published by Japan Society of Ultrasonics in Medicine in Choonpa Igaku
- Vol. 51 (1) , 37-48
The roles of global longitudinal strain imaging in contemporary clinical cardiology
心筋ストレインイメージングは,通常の心エコー検査で測定でき,心血管疾患の治療において重要な役割を果たす.病気の診断を助け,疾患進行の予測や早期の薬物治療介入が可能になり,潜在的な心筋障害を検知する点で臨床的価値がある.ストレインイメージングは,腫瘍循環器分野でもっとも盛んに研究が行われ,臨床でも使用されている.左室(left ventricular: LV)の長軸方向ストレインのベースラインから> 15%の相対的な低下は,早期無症候性LV機能障害のマーカーと考えられ,心保護薬の早期開始につながる可能性をもっている.ストレインイメージングの役割は,心アミロイドーシス,他の心筋症,心臓弁膜症,肺高血圧症,および左室駆出率の保たれた心不全など他の分野にも拡大している.さらに,右室や心房の評価にも応用される.本総説は,臨床において,ストレインイメージングが心血管疾患患者の評価と疾病管理で現在果たしている役割について解説する.
- 1 January 2024
- Published by Japan Society of Ultrasonics in Medicine in Choonpa Igaku
- Vol. 51 (1) , 37-48
The roles of global longitudinal strain imaging in contemporary clinical cardiology
心筋ストレインイメージングは,通常の心エコー検査で測定でき,心血管疾患の治療において重要な役割を果たす.病気の診断を助け,疾患進行の予測や早期の薬物治療介入が可能になり,潜在的な心筋障害を検知する点で臨床的価値がある.ストレインイメージングは,腫瘍循環器分野でもっとも盛んに研究が行われ,臨床でも使用されている.左室(left ventricular: LV)の長軸方向ストレインのベースラインから> 15%の相対的な低下は,早期無症候性LV機能障害のマーカーと考えられ,心保護薬の早期開始につながる可能性をもっている.ストレインイメージングの役割は,心アミロイドーシス,他の心筋症,心臓弁膜症,肺高血圧症,および左室駆出率の保たれた心不全など他の分野にも拡大している.さらに,右室や心房の評価にも応用される.本総説は,臨床において,ストレインイメージングが心血管疾患患者の評価と疾病管理で現在果たしている役割について解説する.
- Open Access
- 5 June 2023
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 10 (6) , 247
Pathophysiologic Contributions of Visceral Adiposity to Left Ventricular Diastolic Dysfunction
Background: Visceral fat produces inflammatory cytokines and may play a major role in heart failure with preserved ejection fraction (HFpEF). However, little data exist regarding how qualitative and quantitative abnormalities of visceral fat would contribute to left ventricular diastolic dysfunction (LVDD). Methods: We studied 77 participants who underwent open abdominal surgery for intra-abdominal tumors (LVDD, n = 44; controls without LVDD, n = 33). Visceral fat samples were obtained during the surgery, and mRNA levels of inflammatory cytokines were measured. Visceral and subcutaneous fat areas were measured using abdominal computed tomography. Results: Patients with significant LVDD had greater LV remodeling and worse LVDD than controls. While body weight, body mass index, and subcutaneous fat area were similar in patients with LVDD and controls, the visceral fat area was larger in patients with LVDD than in controls. The visceral fat area was correlated with BNP levels, LV mass index, mitral e′ velocity, and E/e′ ratio. There were no significant differences in the mRNA expressions of visceral adipose tissue cytokines (IL-2, -6, -8, and -1β, TNFα, CRP, TGFβ, IFNγ, leptin, and adiponectin) between the groups. Conclusions: Our data may suggest the pathophysiological contribution of visceral adiposity to LVDD.
- 5 June 2023
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 10 (6) , 247
Open AccessPathophysiologic Contributions of Visceral Adiposity to Left Ventricular Diastolic Dysfunction
Background: Visceral fat produces inflammatory cytokines and may play a major role in heart failure with preserved ejection fraction (HFpEF). However, little data exist regarding how qualitative and quantitative abnormalities of visceral fat would contribute to left ventricular diastolic dysfunction (LVDD). Methods: We studied 77 participants who underwent open abdominal surgery for intra-abdominal tumors (LVDD, n = 44; controls without LVDD, n = 33). Visceral fat samples were obtained during the surgery, and mRNA levels of inflammatory cytokines were measured. Visceral and subcutaneous fat areas were measured using abdominal computed tomography. Results: Patients with significant LVDD had greater LV remodeling and worse LVDD than controls. While body weight, body mass index, and subcutaneous fat area were similar in patients with LVDD and controls, the visceral fat area was larger in patients with LVDD than in controls. The visceral fat area was correlated with BNP levels, LV mass index, mitral e′ velocity, and E/e′ ratio. There were no significant differences in the mRNA expressions of visceral adipose tissue cytokines (IL-2, -6, -8, and -1β, TNFα, CRP, TGFβ, IFNγ, leptin, and adiponectin) between the groups. Conclusions: Our data may suggest the pathophysiological contribution of visceral adiposity to LVDD.